Skip to main content
OpenTrials
Recruiting

NCT Number: NCT04253301

Feasibility of the InnoVein Valve and Delivery System for Chronic Venous Insufficiency

This objective of this feasibility study is to evaluate the safety of the InnoVein Valve and Delivery System for treatment of chronic venous insufficiency.

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hollywood Private Hospital, Nedlands, Western Australia, Australia

Loading trial locations.

About this study

Chronic Venous Insufficiency occurs when the venous wall and/or valves in the leg veins are not working effectively, making it difficult for blood to return to the heart from the legs.The core etiology of the disease stems from increased venous pressure and incompetent venous valves leading to regurgitation of blood that accumulates in the legs. It has been shown that implantation or recreation of a functional valve can lead to clearance of excess blood and resolution of symptoms.

The InnoVein Valve and Delivery System is a new, investigational biocompatible valve intended to support natural flow in vessels in patients with Chronic Venous Insufficiency. The purpose of this study is to assess the safety of the InnoVein Valve and Delivery System for treatment of Chronic Venous Insufficiency.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Key Inclusion Criteria:

  • Willing and able to provide written Informed Consent
  • Diagnosis of symptomatic non-obstructive chronic valvular insufficiency of the femoral vein
  • Willing and medically able to receive intraprocedural and post-procedural anticoagulation medication
  • Life expectancy >1yr
  • Reflux time >1s in the superficial femoral and/or popliteal vein

Key Exclusion Criteria:

  • Any prior deep vein intervention within 6 months prior to the Index Procedure
  • History of 2+ DVTs
  • Inadequate inflow to the femoral vein or inadequate outflow through the femoral vein, iliac vein, or IVC
  • Current IVC Placement
  • History of pulmonary embolism within 6 months
  • Conditions that increase the risk of device thrombosis or patient bleeding
  • Any planned surgical or interventional procedure within 30 days prior to or after the Index Procedure
  • Investigator or sponsor believes the subject would not benefit, would not be appropriate, be unable to follow-up, or be at high risk for non-compliance with the protocol

Treatment and study plan

InnoVein Valve Treatment

Device

Subjects will have the InnoVein Valve implanted

Primary outcomes

  1. Safety of the InnoVein Valve and Delivery System: Number of Major Adverse Events

    Time frame: 30 Days

    Number of Major Adverse Events

Study contacts

Contact information is provided by the study sponsor or research team.

InnoVen Data Management

CONTACT

[email protected]

650-302-0847

Sponsors and collaborators

Lead sponsor

InnoVein

Industry

Registry information

Important dates

Study start
2020
Primary completion
2022
Study completion
2027
First posted
Feb 5, 2020
Registry last updated
Sep 17, 2021

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.